Aspirin prophylaxis is safe and effective for venous thromboembolism prophylaxis in low-risk patients undergoing aseptic revision total knee arthroplasty

Aims: While aspirin has been widely adopted as an effective method for deep vein thrombosis (DVT) prevention following primary total knee arthroplasty (TKA), concerns remain with regard to its efficacy in the setting of revision TKA (rTKA). However, the risk for thromboembolic events must be weighed against the increased potential for bleeding with more potent anticoagulants. This study aimed to compare venous thromboembolism (VTE) and transfusion rates between patients receiving aspirin with non-aspirin anticoagulation following aseptic rTKA. Methods: We identified patients undergoing aseptic rTKA from 1 January 2016 to 30 April 2023 in a national database. Those with infection, fracture, prior VTE, coagulopathy, or preoperative anticoagulant use were excluded. Patients were grouped by postoperative prophylaxis: aspirin alone or non-aspirin anticoagulants. Patients were allocated to one of two categorical treatment groups. Crossover between groups was permitted where clinically indicated. Propensity score matching (1:1) was performed on demographic details, insurance, comorbidities, postoperative home health use, hospital length of stay ≤ one day, surgery year, and Current Procedural Terminology (CPT) code, yielding 4,585 patients per group. Outcomes included 30- and 90-day DVT, pulmonary embolism (PE), overall VTE, and transfusion. Results: In the matched cohort, aspirin use was associated with lower 90-day DVT (0.8% (n = 38) vs 2.1% (n = 96)), PE (0.6% (n = 26) vs 2.2% (n = 102)), and VTE (1.1% (n = 51) vs 3.3% (n = 152); all p < 0.001). Transfusion was also lower in the aspirin group at 30 days (0.6% (n = 28) vs 1.2% (n = 56); p = 0.003) and 90 days (0.7% (n = 33) vs 1.4% (n = 65); p = 0.002). DVT ultrasound use within 30 days was significantly higher in the non-aspirin group (7.1%; n = 326) compared with aspirin (5.1%; n = 235); p < 0.001), which may partly account for the higher VTE detection. Regression controlling for CPT code confirmed reduced odds of VTE with aspirin. Conclusion: Aspirin is a safe, effective, and noninferior option for VTE prophylaxis following aseptic rTKA in appropriately selected patients.

Authors

Institutions

Publication Details

Journal
The Bone & Joint Journal
Published
2026-04-01
DOI
https://doi.org/10.1302/0301-620x.108b4.bjj-2025-1111.r1
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Aspirin prophylaxis is safe and effective for venous thromboembolism prophylaxis in low-risk patients undergoing aseptic revision total knee arthroplasty

G. Lee, Alejandro González Della Valle, Billy I. Kim, Fred D. Cushner et al.
The Bone & Joint Journal
Venous Thromboembolism Diagnosis and Management
article

Aspirin prophylaxis is safe and effective for venous thromboembolism prophylaxis in low-risk patients undergoing aseptic revision total knee arthroplasty

G. Lee, Alejandro González Della Valle, Billy I. Kim, Fred D. Cushner, Peter K. Sculco
article en

Abstract

Aims: While aspirin has been widely adopted as an effective method for deep vein thrombosis (DVT) prevention following primary total knee arthroplasty (TKA), concerns remain with regard to its efficacy in the setting of revision TKA (rTKA). However, the risk for thromboembolic events must be weighed against the increased potential for bleeding with more potent anticoagulants. This study aimed to compare venous thromboembolism (VTE) and transfusion rates between patients receiving aspirin with non-aspirin anticoagulation following aseptic rTKA. Methods: We identified patients undergoing aseptic rTKA from 1 January 2016 to 30 April 2023 in a national database. Those with infection, fracture, prior VTE, coagulopathy, or preoperative anticoagulant use were excluded. Patients were grouped by postoperative prophylaxis: aspirin alone or non-aspirin anticoagulants. Patients were allocated to one of two categorical treatment groups. Crossover between groups was permitted where clinically indicated. Propensity score matching (1:1) was performed on demographic details, insurance, comorbidities, postoperative home health use, hospital length of stay ≤ one day, surgery year, and Current Procedural Terminology (CPT) code, yielding 4,585 patients per group. Outcomes included 30- and 90-day DVT, pulmonary embolism (PE), overall VTE, and transfusion. Results: In the matched cohort, aspirin use was associated with lower 90-day DVT (0.8% (n = 38) vs 2.1% (n = 96)), PE (0.6% (n = 26) vs 2.2% (n = 102)), and VTE (1.1% (n = 51) vs 3.3% (n = 152); all p < 0.001). Transfusion was also lower in the aspirin group at 30 days (0.6% (n = 28) vs 1.2% (n = 56); p = 0.003) and 90 days (0.7% (n = 33) vs 1.4% (n = 65); p = 0.002). DVT ultrasound use within 30 days was significantly higher in the non-aspirin group (7.1%; n = 326) compared with aspirin (5.1%; n = 235); p < 0.001), which may partly account for the higher VTE detection. Regression controlling for CPT code confirmed reduced odds of VTE with aspirin. Conclusion: Aspirin is a safe, effective, and noninferior option for VTE prophylaxis following aseptic rTKA in appropriately selected patients.

The Bone & Joint JournalVol. 108-B(4)
Hospital for Special Surgery (US)
Good health and well-being
Openalex Percentile: Top 32%
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.